Importantly, our results aligned with these claims; NMS-E973 exhibited remarkable antitumor efficacy against CRC in vitro, and the combination of NMS-E973 with the downregulation of PUS7 significantly reduced CRC metastasis in contrast to NMS-E973 monotherapy in vivo. Here, PUS7 is linked to colorectal carcinoma.